Scope of report
- The report provides a snapshot of the global therapeutic landscape of Fabry’s disease.
- The report assesses Fabry’s disease pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
- The report reviews Fabry’s disease pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development for Fabry’s disease ranging from discovery to pre-registration and undisclosed stages.
Research Corporation Technologies, Shire, Genzyme Corporation, Avigen, Large Scale Biology Corporation (CEASED), Amicus Therapeutics, Protalix Biotherapeutics, iBio Inc, Green Cross, ISU Abxis, Actelion Pharmaceuticals, Bio Sidus S.A., JCR Pharmaceuticals, AVROBIO, Greenovation Biotech, Sangamo Therapeutics
Alpha-antitrypsin – Arriva/Hyland Immuno, Recombinant human alpha-1 antitrypsin, VX 563, CTX 100, Small interfering RNA-based therapeutics, AGTC 0106, Alpha-1 antitrypsin deficiency therapy, Alpha-1 antitrypsin deficiency gene therapy, Alpha-1 antitrypsin, RNAi therapeutics, Human amniocyte-derived protein therapeutics, AAT-Fc – InhibRx, Biotherapeutic proteins
Format: Microsoft Excel
- Single Use: $300
- Site License: $500
- Global License: $800